It is not clear if the quotes attributed to Dr. Chambers are based on a more recent interview, or the one from 2003. Still, this article does revive the comments that Macugen may need to do more carcinogenicity studies, either before or after they get marketing approval.
It has a table on page 3 listing various AMD drugs under development (including squalamine), and what stage they are in.
It mentions the FDA advisory panel meeting on August 27, so it is probably just a heads-up or a reminder.
Market Data 
Markets 
AI
